0001209191-17-065415.txt : 20171213
0001209191-17-065415.hdr.sgml : 20171213
20171213161007
ACCESSION NUMBER: 0001209191-17-065415
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171211
FILED AS OF DATE: 20171213
DATE AS OF CHANGE: 20171213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vachon Mark
CENTRAL INDEX KEY: 0001614018
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 171253941
MAIL ADDRESS:
STREET 1: GOODWIN PROCTER LLP
STREET 2: 53 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-11
0
0001293971
bluebird bio, Inc.
BLUE
0001614018
Vachon Mark
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2017-12-11
4
M
0
6000
30.47
A
8000
D
Common Stock
2017-12-11
4
S
0
300
210.5667
D
7700
D
Common Stock
2017-12-11
4
S
0
1421
212.315
D
6279
D
Common Stock
2017-12-11
4
S
0
800
217.0875
D
5479
D
Common Stock
2017-12-11
4
S
0
2200
218.0636
D
3279
D
Common Stock
2017-12-11
4
S
0
1979
219.50
D
1300
D
Common Stock
2017-12-11
4
S
0
300
212.65
D
1000
D
Stock Option
30.47
2017-12-11
4
M
0
6000
0.00
D
2024-07-16
Common Stock
6000
8000
D
The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2017.
The range in prices for the transaction reported on this line was $210.4000 to $210.9000. The average weighted price was $210.5667. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $211.6500 to $212.6000. The average weighted price was $212.3150. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $216.9000 to $217.2500. The average weighted price was $217.0875. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $218.0000 to $218.2000. The average weighted price was $218.0636. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range of prices for the transaction reported on this line was $221.5500 to $221.8500. The average weighted price was $221.6500. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option vests ratably over three years in annual installments, commencing on July 16, 2014.
/s/ Jason F. Cole, Attorney-in-Fact
2017-12-13